Floatz logo

ama1-c1

Malaria

National Institute of Allergy and Infectious Diseases (NIAID)vaccinePhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Malaria cohort.

Asset / SponsorPhaseRating
Artesunate
University of Khartoum
Phase 4BBB
COA566
Novartis
Phase 4BB
Hydroxyurea
Indiana University
Phase 3BB
Quinine
University of Khartoum
Phase 4BB
sar97276a
Sanofi
Phase 2CCC

View all 13 →

Same molecule, other indications

ama1-c1 is also rated in:

Plasmodium falciparum malariaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →